Electrical Substance Clearance from Brain Parenchyma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and cerebral amyloid angiopathy (CAA) are inadequate in effectively clearing amyloid beta and tau proteins from the brain, which contribute to the progression of these conditions.
Innovation Solution
The use of an extracranial electrode placed outside the skull and a cerebrospinal fluid (CSF) electrode implanted in the brain's ventricular system, with control circuitry to drive electrical currents between them to clear amyloid beta and tau proteins from the brain parenchyma into the CSF system or subarachnoid space, utilizing direct current or non-excitatory currents with specific amplitudes and pulse durations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If electrical stimulation is applied to clear amyloid beta and tau proteins from the brain, then the clearance effectiveness is improved, but the risk of excitatory effects on brain tissue increases
Solution Approach 1:
The patent applies non-excitatory electrical parameters (specific amplitude ranges and pulse durations) to achieve protein clearance without causing excitatory effects on brain tissue. By carefully controlling electrical parameters, the system effectively clears amyloid beta and tau proteins while avoiding harmful stimulation of neural activity.
2Productivity
If direct current is applied with higher amplitude to enhance clearance, then the clearance rate is improved, but the energy consumption and potential tissue damage increase
Solution Approach 1:
The patent applies electrical current at optimized amplitudes that are sufficient to achieve effective protein clearance without excessive energy consumption. The system uses just enough electrical stimulus to drive amyloid beta and tau proteins into CSF-filled spaces, avoiding both under-treatment and over-treatment with excessive energy.
3Manufacturing precision
If electrodes are implanted deeper in the brain to improve clearance precision, then the clearance precision is improved, but the surgical complexity and risk increase
Solution Approach 1:
The patent uses cerebrospinal fluid-filled spaces (ventricles, subarachnoid space) as intermediary collection points for cleared proteins. Instead of requiring deep brain electrodes to directly remove proteins, the system stimulates proteins to migrate to CSF-filled spaces where they are naturally cleared, simplifying electrode placement while maintaining effective clearance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively clears amyloid beta and tau proteins from the brain, potentially slowing the progression of Alzheimer's disease and CAA by removing pathological substances from the brain parenchyma into CSF-filled spaces or dural sinuses, thereby addressing the accumulation issues.
Implementation Method 1
control circuitry, configured to drive the extracranial and the CSF electrodes to clear a substance from brain parenchyma of the subject into the ventricular system of the brain
Implementation Method 2
utilizing direct current or non-excitatory currents with specific amplitudes and pulse durations
Data Source
AI summary
Apparatus is provided that includes an extracranial electrode, configured to be placed outside and in electrical contact with a skull of a subject identified as at risk of or suffering from a disease; and a cerebrospinal fluid (CSF) electrode, configured to be implanted in a ventricular system of a brain of the subject. Control circuitry is configured to drive the extracranial and the CSF electrodes to clear a substance from brain parenchyma of the subject into the ventricular system of the brain. Other embodiments are also described.